Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
2018 Jul 16
both cell line- and patient-derived BRAFV600E tumors exhibit stronger and more sustained pharmacodynamic inhibition (>90% for 8 hours) and improved survival compared to mutant KRAS-expressing tumors
ClH/c1-2-28-20(25)23-10-9-16(13-23)12-22(11-15-3-5-17(21)6-4-15)14-18-7-8-19(29-18)24(26)27
and cell cycle arrest of MLL-AF6-transformed cells
ML364 has an IC50 of 1
PF-562271 besylate - CAS# 939791-38-5 aminophen metabolite 3-hydroxy-acetaminophen 2018 Jul 16PF 562271 Besylate, also known as PF 562,271 and PF 271, is an orally bioavailable small molecule and ATP competitive focal adhesion kinase (FAK) inhibitor with potential antineoplastic and antiangiogenic activities. PF 562271 inhibits the tyrosine kinase FAK, and to a lesser extent, proline rich tyrosine kinase (PYK2), which may inhibit tumor cell migration, proliferation, and survival. Note: PF 562271 benzesulfonate is also called PF 562271
US$ 38.00
US$ 65.00
US$ 85.00
US$ 95.00
US$ 80.00
US$ 130.00
US$ 140.00
US$ 120.00
US$ 145.00
US$ 68.00
US$ 85.00